home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

166.80 -18.70 (-10.08%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise ↗

December 06, 2023

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX. ↗

December 01, 2023

Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. ↗

November 23, 2023

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.

Via Chartmill

CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News ↗

November 17, 2023

CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating ↗

November 17, 2023

Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.

Via Investor's Business Daily

Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade ↗

November 10, 2023

Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.

Via Investor's Business Daily

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗

November 07, 2023

Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. ↗

November 02, 2023

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Earnings Outlook For Neurocrine Biosciences ↗

October 30, 2023

Via Benzinga

Why Is Neurocrine Biosciences Stock Trading Lower Today? ↗

November 10, 2023

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)

Via Benzinga

3 Biotech Moonshots to Bet on the Future of Health ↗

November 06, 2023

Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.

Via InvestorPlace

Topics Intellectual Property

Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗

November 02, 2023

On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78

Via Investor's Business Daily

Raymond James Maintains Outperform Rating for Neurocrine Biosciences: Here's What You Need To Know ↗

November 01, 2023

Via Benzinga

Despite its growth, NASDAQ:NBIX remains within the realm of affordability. ↗

October 16, 2023

Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

October 12, 2023

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗

October 11, 2023

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

What 22 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

October 06, 2023

Via Benzinga

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗

September 28, 2023

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Why Is Neurocrine Biosciences Shares Trading Higher Today? ↗

October 05, 2023

Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH)...

Via Benzinga

NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. ↗

September 27, 2023

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.

Via Chartmill

NASDAQ:NBIX qualifies as a high growth stock and is consolidating. ↗

September 26, 2023

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

September 22, 2023

Why NEUROCRINE BIOSCIENCES INC ( NASDAQ:NBIX ) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Analyst Expectations for Neurocrine Biosciences's Future ↗

September 13, 2023

Via Benzinga

GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

September 13, 2023

Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in...

Via Benzinga

Analyst Ratings for Neurocrine Biosciences ↗

August 21, 2023

Via Benzinga

Analyst Ratings for Neurocrine Biosciences ↗

August 02, 2023

Via Benzinga

What's Going On With Neurocrine Biosciences Stock Today? ↗

September 12, 2023

Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due...

Via Benzinga

Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High? ↗

September 12, 2023

The company is working on a treatment for a disorder than can cause children to begin puberty early.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 08, 2023

Via Benzinga

FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning ↗

August 21, 2023

The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com